左西孟旦在心血管疾病的研究进展

Research Progress of Levosimendan in Cardiovascular Diseases

左西孟旦LS (Levosimendan, LS)作为一种新型钙增敏剂,其增加心肌收缩力、扩张外周血管和冠状动脉的同时,还具有肝脏、肾脏、肺等器官保护作用。动物实验中发现,LS还具有抗炎、抗氧化、抗血栓形成和前纤维蛋白溶解作用。LS的作用特点是增强心肌收缩力的同时不增加心肌耗氧,不会对舒张功能产生影响,因此适用于需要增加心肌收缩力的急性失代偿性心力衰竭(Acute Decom-pensated Heart Failure, ADHF)患者的短期治疗。此外,在心源性休克、感染性休克、肺心病、扩张型心肌病(Dilated Cardiomyopathy, DCM)的治疗中以及外科围手术期联合应用LS,患者心功能改善更加明显,且安全性较好。

Levosimendan (LS), as a new calcium sensitizer, can increase myocardial contractility, dilate pe-ripheral and coronary arteries, and protect organs such as liver, kidney and lung. Animal experi-ments have found that LS also has anti-inflammatory, anti-oxidation, anti-thrombosis and profibri-nolytic effects. LS is characterized by enhancing myocardial contractility without increasing myo-cardial oxygen consumption and having no effect on diastolic capacity. It is suitable for the short-term treatment of Acute Decompensated Heart Failure (ADHF) that needs to increase myo-cardial contractility. In addition, LS can significantly improve cardiac function and relieve clinical symptoms in patients with cardiogenic shock, septic shock, pulmonary heart disease, dilated car-diomyopathy (DCM) and surgical perioperative period.